MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer-Trial in progress.

被引：0
|
作者：
Bekaii-Saab, Tanios S.
Van Cutsem, Eric
Tabernero, Josep
Siena, Salvatore
Yoshino, Takayuki
Nakamura, Yoshiaki
Raghav, Kanwal Pratap Singh
Cercek, Andrea
Heinemann, Volker
Adelberg, David E.
Ward, James Edward
Yang, Shan
Andre, Thierry
Strickler, John H.
机构：
[1] Mayo Clin, Scottsdale, AZ USA
[2] Univ Hosp Gasthuisberg, Leuven, Belgium
[3] Univ Leuven, Leuven, Belgium
[4] Vall DHebron Univ Hosp & Inst Oncol VHIO, Barcelona, Spain
[5] Grande Osped Metropolitano Niguarda, Milan, Italy
[6] Univ Milan, Milan, Italy
[7] Natl Canc Ctr Hosp Japan East, Kashiwa, Chiba, Japan
[8] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[9] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[10] Univ Munich, Munich, Germany
[11] Merck & Co Inc, Kenilworth, NJ USA
[12] Seagen Inc, Bothell, WA USA
[13] Sorbonne Univ, Paris, France
[14] Hop St Antoine, INSERM Instabil Microsatellites & Canc, Paris, France
[15] Duke Univ, Med Ctr, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS261
引用
收藏
页码：TPS261 / TPS261
页数：1
相关论文
共 50 条
  • [21] Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+metastatic breast cancer (HER2CLIMB-05, trial in progress)
    Hamilton, Erika
    Tsurutani, Junji
    Sohn, Joohyuk
    Curigliano, Giuseppe
    O'Sullivan, Ciara C.
    Martin, Miguel
    Tryfonidis, Konstantinos
    Santarpia, Libero
    Yang, Shan
    Dieras, Veronique
    CANCER RESEARCH, 2023, 83 (08)
  • [22] Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)
    Oki, Eiji
    Emi, Yasunori
    Yamanaka, Takeharu
    Uetake, Hiroyuki
    Muro, Kei
    Takahashi, Takao
    Nagasaka, Takeshi
    Hatano, Etsuro
    Ojima, Hitoshi
    Manaka, Dai
    Kusumoto, Tetsuya
    Katayose, Yu
    Fujiwara, Toshiyoshi
    Yoshida, Kazuhiro
    Unno, Michiaki
    Hyodo, Ichinosuke
    Tomita, Naohiro
    Sugihara, Kenichi
    Maehara, Yoshihiko
    BRITISH JOURNAL OF CANCER, 2019, 121 (03) : 222 - 229
  • [23] MOUNTAINEER: Open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer
    Strickler, J.
    Ng, K.
    Cercek, A.
    Fountzilas, C.
    Sanchez, F.
    Hubbard, J.
    Wu, C.
    Stecher, M.
    Walker, L. N.
    Bekaii-Saab, T.
    ANNALS OF ONCOLOGY, 2020, 31 : S460 - S461
  • [24] Phase 2 randomized controlled trial of intravenous or intraperitoneal paclitaxel plus mFOLFOX6 vs. mFOLFOX6 as first-line treatment of advanced gastric cancer
    Zhao, Shen
    Su, Liyu
    Chen, Yigui
    Li, Xiaofeng
    Lin, Peicheng
    Chen, Wujin
    Fang, Wenzheng
    Zhu, Jinfeng
    Li, Hui
    Ren, Liping
    Liu, Jie
    Hong, Yanni
    Lin, Shaowei
    Fan, Nanfeng
    Lin, Rongbo
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [25] A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients
    Van Cutsem, E.
    Prenen, H.
    D'Haens, G.
    Bennouna, J.
    Carrato, A.
    Ducreux, M.
    Bouche, O.
    Sobrero, A.
    Latini, L.
    Staines, H.
    Oum'Hamed, Z.
    Dressler, H.
    Studeny, M.
    Capdevila, J.
    ANNALS OF ONCOLOGY, 2015, 26 (10) : 2085 - 2091
  • [26] Phase III study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+metastatic breast cancer (HER2CLIMB-05, trial in progress)
    Dieras, V. C.
    Martin Jimenez, M.
    O'Sullivan, C. C. M.
    Sohn, J.
    Tryfonidis, K.
    Santarpia, L.
    Yang, S.
    Hamilton, E. P.
    ANNALS OF ONCOLOGY, 2022, 33 : S222 - S222
  • [27] Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)
    Schmoll, Hans-Joachim
    Cunningham, David
    Sobrero, Alberto
    Karapetis, Christos S.
    Rougier, Philippe
    Koski, Sheryl L.
    Kocakova, Ilona
    Bondarenko, Igor
    Bodoky, Gyoergy
    Mainwaring, Paul
    Salazar, Ramon
    Barker, Peter
    Mookerjee, Bijoyesh
    Robertson, Jane
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (29) : 3588 - 3595
  • [28] 5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study
    Hecht, J. Randolph
    Mitchell, Edith P.
    Yoshino, Takayuki
    Welslau, Manfred
    Lin, Xun
    Maneval, E. Dna Chow
    Paolini, Jolanda
    Lechuga, Maria Jose
    Kretzschmar, Albrecht
    CANCER MANAGEMENT AND RESEARCH, 2015, 7 : 165 - 173
  • [29] Phase I trial of erlotinib (E), modified FOLFOX6 (mFOLFOX6), and bevacizumab (B) as first-line therapy for metastatic colorectal cancer (MCRC)
    Singh, D.
    Rath, L.
    Bokar, J. A.
    Brell, J. M.
    Cooney, M. M.
    Dowlati, A.
    Gibbons, J.
    Nock, C. J.
    Savvides, P.
    Krishnamurthi, S. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [30] Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.
    Yoshino, Takayuki
    Watanabe, Jun
    Shitara, Kohei
    Yasui, Hirofumi
    Ohori, Hisatsugu
    Shiozawa, Manabu
    Yamazaki, Kentaro
    Oki, Eiji
    Sato, Takeo
    Naitoh, Takeshi
    Komatsu, Yoshito
    Kato, Takeshi
    Hihara, Masamitsu
    Soeda, Junpei
    Yamamoto, Kouji
    Akagi, Kiwamu
    Ochiai, Atsushi
    Uetake, Hiroyuki
    Tsuchihara, Katsuya
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
12345